A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
- 31 January 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (1), 47-51
- https://doi.org/10.1016/0959-8049(95)00398-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Multidrug ResistancePublished by Springer Nature ,2011
- Activity of taxol (T) by 3 h infusion in breast cancer patients (pts) with clinical resistance to anthracyclines (A)European Journal Of Cancer, 1993
- High-dose taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapyEuropean Journal Of Cancer, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Salvage Chemotherapy for Breast Cancer Patients Treated with Adjuvant Adriamycin-Containing RegimenOncology, 1990
- Taxol produces a predominantly sensory neuropathyNeurology, 1989
- Multidrug Resistance1JNCI Journal of the National Cancer Institute, 1988
- Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division.The Journal of cell biology, 1983
- Promotion of microtubule assembly in vitro by taxolNature, 1979
- Antineoplastic Agents from PlantsAnnual Review of Pharmacology and Toxicology, 1977